Mark Erlander News Today

RAS-mutated mCRC– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulti...

Onvansertib either alone or with standard of care many benefit patients with metastatic pancreatic ductal adenocarcinoma and those with pretreated SCLC.

Cardiff Oncology, Inc. (NASDAQ: CRDF) shares are trading higher Tuesday after-hours after the company announced clinical data in pancreatic cancer and small cell lung cancer, including single-agent activity

Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% and mPFS of 5.0...

Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical...

/PRNewswire/ -- About 9.4% of the world population is aged 65 or above. Older people typically consume more medicines than the people in other age group...

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug...

 - Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA -  - First-line mCRC represents substantial increase in patient...

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug...

Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective...